This extensive report provides a unique analysis of the likely impact of generic competition in the US pharma market. Now you can:
- Identify the 150 products which could be subject to generic competition over the next 5 years - Evaluate the level of impact on each product - Assess the impact of generic competition on 14 leading branded companies - Understand the strategies being used by companies in defence of their products’ position
Key questions answered in this report:
- Which companies are at greater or lesser risk of generic competition by 2012 and what will be the impact on revenues? - What strategies has Abbott successfully employed in defence of Depakote and Tricor? - Who is benefiting from the unresolved biosimilar approval process? - AstraZeneca could have US$5.31 billion of revenue at risk by 2012 – what are the products affected and when will the impact be felt? - What lessons can be learned from the ongoing Apotex/BMS and SA litigation in relation to the world’s second best selling drug Plavix? - There is much discussion about generic competition to Lipitor, but what other products are at risk in Pfizer’s portfolio? - Why has Wyeth not sued Sun Pharmaceutical over its extended release tablet for Effexor?
